Clinical trials
PSMA clinical trials
Below are recruiting psma clinical trials, each written for real people, not researchers. We’re tracking 192 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05354375RecruitingPhase 1
PSMA-targeted CAR-T cell therapy for resistant prostate cancer
This Phase 1 study tests whether lab-made immune cells (CAR-T) that target PSMA can treat prostate cancer that keeps growing despite hormone treatment. It may help people whose disease no longer responds to standard endocrine (hormone-blocking) therapy.
Xuzhou, JiangsuAges 18–75 - NCT06219746Recruiting
New imaging scan for high-risk prostate cancer staging
This trial tests a special type of scan (99mTc-MIP-1404 SPECT/CT) to see how well it can detect the spread of high-risk prostate cancer. It may help doctors better understand the stage of the disease before deciding on treatment.
Turku, Southwest FinlandAges 18 years+ - NCT04642027RecruitingPhase 3
PSMA scan-guided salvage radiation after prostate surgery
This trial tests whether using a specialized PSMA PET scan to guide radiation can better treat prostate cancer that returns after prostate surgery. It targets the “prostate bed” area with a shorter, stronger radiation schedule (hypofractionated) to control rising PSA levels.
Arnhem, GelderlandAges 18–80 - NCT03198052RecruitingPhase 1
CAR-T cell therapy for cancers with specific protein targets
This Phase 1 study tests CAR-T cells that are engineered to recognize several cancer “markers” (specific proteins) found on some advanced cancers. It may help by directing the patient’s own immune cells to attack cancer, but eligibility depends on matching the required protein markers.
Guangzhou, GuangdongAges 18–75 - NCT07798778RecruitingEarly Phase 1
New drug for advanced prostate cancer that has stopped responding to hormone therapy
This trial tests a new drug called SRT-017 for men with advanced prostate cancer that has stopped responding to standard hormone therapy. The drug targets a marker on cancer cells (PSMA) and may help slow the disease. The study will check if it is safe and effective.
Wuxi, JiangsuAges 18 years+ - NCT07788625Recruiting
Focal therapy for prostate cancer not visible on MRI
This study tests a new way to treat prostate cancer that is not visible on MRI but is detected by a special PET scan. The treatment is a focal therapy that targets only the cancer while sparing healthy tissue, and it aims to control the cancer with fewer side effects.
Hong Kong, 香港島Ages 50 years+ - NCT07707232Recruiting
Using AI to read PSMA PET/CT reports for prostate cancer
This trial uses a computer program (large language model) to help doctors read Chinese PSMA PET/CT reports. The goal is to see if the AI can accurately identify key details about prostate cancer, like where it has spread, which may help make staging and treatment decisions faster.
Wenzhou, ZhejiangAges 18 years+ - NCT07691697Recruiting
Targeted radiation for limited prostate cancer spread
This trial tests whether giving focused radiation to a small number of growing prostate cancer spots can help control the disease while you continue your current systemic treatment. It may delay the need to switch treatments and is for people whose cancer has spread to only a few places.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT07690306Enrolling by invitation
AI study to improve prostate cancer diagnosis with MRI and PSMA PET scans
This study is testing whether artificial intelligence can better predict prostate cancer by combining two types of scans (MRI and PSMA PET) along with your medical history, PSA, and biopsy results. If you have already had these scans and a biopsy, your information may help researchers develop a more accurate, non-invasive diagnostic tool.
Los Angeles, CaliforniaAges 18 years+ - NCT07641049RecruitingPhase 1
CAR-NK Cell Therapy for Advanced Prostate Cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to target and fight advanced prostate cancer that has stopped responding to hormone treatments. The cells are engineered to recognize and attack cancer cells that have specific markers (PSMA and PSCA) on their surface.
Shenzhen, GuangdongAges 18 years+ - NCT06706921RecruitingPhase 4
Predicting treatment success with PET scans in prostate cancer
This study looks at whether a special PET scan can help predict how well a targeted radiation therapy (LuPSMA) works in men with advanced prostate cancer that has spread. You would get several PET scans before and after treatment to see if the scan results can forecast your outcome.
Los Angeles, CaliforniaAges 18 years+ - NCT07611110RecruitingPhase 3
AZD2265 vs standard care for advanced prostate cancer
This trial tests a new cancer-fighting drug called AZD2265 against standard treatment for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. You may qualify if your cancer previously responded to PSMA-targeted radiation treatments but is now growing again.
Dothan, AlabamaAges 18 years+ - NCT06720532Recruiting
Kidney function in men with prostate cancer getting a new targeted radiation therapy
This study looks at how a targeted radiation therapy called 177Lu-PSMA affects kidney function in men with a type of advanced prostate cancer. It aims to understand risk factors to help guide safe treatment.
MunichAges 18 years+ - NCT07569926RecruitingPhase 4
Fluciclovine PET scan for prostate cancer recurrence detection
This study tests whether a newer type of imaging scan (called fluciclovine PET) can find where prostate cancer has come back when an earlier scan (PSMA PET) didn't show clear results. The goal is to help doctors better plan treatment for men whose cancer has returned after surgery or radiation.
San Diego, CaliforniaAges 18 years+ - NCT07568613Recruiting
PSMA PET/CT versus MRI for mapping prostate cancer
This trial compares two imaging techniques—PSMA PET/CT and MRI—to see which one better finds and outlines prostate cancer tumors. You'll receive both scans to help doctors understand which method works best for newly diagnosed prostate cancer.
LimassolAges 18 years+ - NCT07567521RecruitingPhase 1/Phase 2
TRC003 for Advanced Prostate Cancer That Has Progressed
This early-stage trial tests a new drug called TRC003 for men with advanced prostate cancer that has spread and stopped responding to standard treatments. The drug is designed to target cancer cells that show a specific marker called PSMA.
Taiyuan, ShanxiAges 18 years+ - NCT06696326Recruiting
New PET scan for prostate cancer detection
This study tests a new type of PET/CT scan that uses a special tracer (68Ga-MY6349) to better see prostate cancer in the body. It may help doctors find cancer that has come back or spread, so you can get the right treatment sooner.
Xiamen, FujianAges 18–90 - NCT07553754Recruiting
Blood test to predict prostate cancer spread to bones
This study examines special particles in your blood called exosomes to see if they can predict whether prostate cancer might spread to your bones. Researchers will collect a blood sample before any cancer treatment to look for RNA signatures that might indicate bone metastasis risk.
Lanzhou, GansuAges 18 years+ - NCT06496581RecruitingPhase 3
Adding a targeted radiation drug for prostate cancer that hasn't responded well to initial treatment
This trial tests if adding a radioactive drug called 177Lu-PSMA-617 to standard therapy helps men whose prostate cancer has spread and hasn't responded well to initial hormone therapy. It's for men whose PSA level is still detectable after 6-8 months of treatment.
AngersAges 18–80 - NCT07537010RecruitingPhase 1
3D1015 Injection for Advanced Prostate Cancer
This Phase 1 trial tests a new injectable treatment called 3D1015 for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug is designed to target cancer cells using a special imaging marker that shows up on PET scans.
Wuxi, JiangsuAges 18 years+ - NCT06398613Recruiting
Using PSMA PET scan before prostate cancer surgery
This trial is testing whether a special scan (PSMA PET/CT) before surgery can help doctors decide if you need to remove lymph nodes. It is for men with high-risk prostate cancer who are already planning to have robot-assisted prostate removal.
OsloAges 18 years+ - NCT06758882RecruitingPhase 2
Surgery with or without apalutamide for high-risk prostate cancer that has spread a little
This trial tests whether adding the drug apalutamide before and after surgery helps men with high-risk prostate cancer that has spread to a few spots (seen on a special PET scan). You would also receive standard hormone therapy.
Torino, ToAges 18–80 - NCT06769893Recruiting
New PET scan for kidney cancer staging and monitoring
This study tests a new type of PET scan that uses a tracer called 68Ga-RCCB6 to see kidney cancer more clearly. It compares this scan to another PET scan (68Ga-PSMA) to help doctors stage the cancer, check treatment response, and detect any return of the disease.
Xi'an, China, ShaanxiAges 18–75 - NCT06657131Recruiting
PSMA PET scan for prostate cancer recurrence
This trial looks at how well a special PET scan (called PSMA PET) can find prostate cancer that has come back after treatment. It uses a radioactive tracer to spot cancer cells. Your doctor may already have ordered this scan as part of your regular care.
Düsseldorf, North Rhine-WestphaliaAges 18 years+
Hear when a new PSMA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for psma?
- Yes. Clin2 currently lists 192 recruiting psma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a psma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a psma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.